Assessing Changes in Limited-Stage DLBCL Care Over the Years
We revisit the many eras of DLBCL care, from a time before the availability of rituximab and PET scans to how it is being treated today.
DLBCL Insights
Can Chronotherapy in DLBCL Improve Therapeutic Outcomes?
Among the many lines of research surrounding DLBCL, researchers are investigating whether chronotherapy can impact clinical outcomes.
Case Study Highlights the Incidental Discovery of DLBCL Presurgery
Researchers described the case study of a patient planned for orthopedic surgery who was incidentally discovered to have DLBCL.
Second-Line Management of DLBCL Explored
For patients with diffuse large B-cell lymphoma who fail first-line therapy, a few second-line options remain.
Immunotherapy May Lead to Durable Remission in DLBCL
The need for therapeutic options capable of providing durable remission and long-term survival for patients with high-risk DLBCL has staggered.
Factors to Consider in the Treatment of Limited-Stage DLBCL
About a quarter of patients with diffuse large B-cell lymphoma (DLBCL) present with limited stage (LS-DLBCL). LS-DLBCL is usually defined as Ann Arbor stages 1 to 2 disease (tumor is restricted to above or below the diaphragm) with largest mass size < 10 cm in diameter. However, no standard definition exists. According to Rojek and…
Managing Treatment Resistance in Patients With DLBCL
The R-CHOP regimen (consisting of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL). Improvements in patient outcomes have become widely known, with long-term disease-free survival rates increasing to 60%-70%. However, some patients (up to 40%) develop relapsed or refractory disease (rrDLBCL), which has a poor prognosis.…
Staging Diffuse Large B-Cell Lymphoma and Monitoring Treatment Response
Staging diffuse large B-cell lymphoma and monitoring treatment response are 2 ways to predict the prognosis of patients with the disease.
The Many Uses of Palliative Radiotherapy in Diffuse Large B-Cell Lymphoma
Here we present recommendations for palliative radiotherapy in DLBCL as suggested by Wright et al in Clinical Lymphoma, Myeloma and Leukemia.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in DLBCL Insights
Loading... 
Loading...